Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2, Randomized, Double-blind, Placebo-controlled, Fixed-dose, Parallel-group, Multicenter, Efficacy, and Safety Study of MT-9938 for Treatment of Uremic Pruritus in Subjects With End-stage Renal Disease Receiving Hemodialysis
Brief Summary: This study is being conducted to investigate the efficacy of MT-9938 compared with placebo after 2 weeks, to continue to evaluate efficacy for an additional 6 weeks, and to explore the effect of a reduction in itching intensity on health-related Quality of Life(QoL) domains, especially those which recent research suggests have a positive correlation with overall survival for this patient group. The study will consist of the following phases: Screening (1 to 2 weeks), Run in (1 week), double-blind Treatment (8 weeks), Washout (1 week) culminating in a Follow-up Visit (1 week after the last dose).


Options:
A: Arm Label: montelukast; Type: ACTIVE_COMPARATOR; Interventions: Drug: Montelukast | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Montelukast; Assigned to Arm(s): montelukast | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
B: Arm Label: MT-9938 2.5μg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nalfurafine hydrochloride(MT-9938) 2.5μg | Arm Label: MT-9938 5μg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nalfurafine hydrochloride(MT-9938) 5μg | Arm Label: MT-9938 10μg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nalfurafine hydrochloride(MT-9938) 10μg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Nalfurafine hydrochloride(MT-9938) 2.5μg; Assigned to Arm(s): MT-9938 2.5μg | Intervention Type: DRUG; Name: Nalfurafine hydrochloride(MT-9938) 5μg; Assigned to Arm(s): MT-9938 5μg | Intervention Type: DRUG; Name: Nalfurafine hydrochloride(MT-9938) 10μg; Assigned to Arm(s): MT-9938 10μg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: hemodialysis+hemoperfusion (HA330); Type: EXPERIMENTAL; Interventions: Other: hemodialysis only, Other: hemodialysis plus hemoperfusion(HA330) | Arm Label: hemodialysis+hemoperfusion (HA130); Type: EXPERIMENTAL; Interventions: Other: hemodialysis only, Other: hemodialysis plus hemoperfusion(HA130) | Arm Label: hemodialysis only; Type: ACTIVE_COMPARATOR; Interventions: Other: hemodialysis only | Intervention Type: OTHER; Name: hemodialysis only; Assigned to Arm(s): hemodialysis only, hemodialysis+hemoperfusion (HA130), hemodialysis+hemoperfusion (HA330) | Intervention Type: OTHER; Name: hemodialysis plus hemoperfusion(HA330); Assigned to Arm(s): hemodialysis+hemoperfusion (HA330) | Intervention Type: OTHER; Name: hemodialysis plus hemoperfusion(HA130); Assigned to Arm(s): hemodialysis+hemoperfusion (HA130)
D: Arm Label: a treatment group; Type: EXPERIMENTAL; Interventions: Drug: PG102P | Arm Label: a control group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: PG102P; Assigned to Arm(s): a treatment group | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): a control group

Answer: B